Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from Chimeric Therapeutics Ltd. ( (AU:CHM) ) is now available.
Chimeric Therapeutics Ltd. announced the resignation of Paul Hopper from his position as a director, effective November 25, 2025. This change in the board may impact the company’s strategic direction and investor confidence, given Hopper’s significant holdings of 21,232,142 ordinary shares and 31,580,882 options. The transition could influence the company’s operations and its positioning in the competitive biotechnology market.
More about Chimeric Therapeutics Ltd.
Chimeric Therapeutics Ltd. operates in the biotechnology industry, focusing on the development of innovative cell therapies for cancer treatment. The company is known for its work in advancing chimeric antigen receptor T cell (CAR-T) therapies, aiming to improve outcomes for cancer patients.
Technical Sentiment Signal: Sell
Current Market Cap: A$10.93M
Find detailed analytics on CHM stock on TipRanks’ Stock Analysis page.